Sensus Healthcare (NASDAQ:SRTS) Downgraded by Wall Street Zen to Sell

Wall Street Zen cut shares of Sensus Healthcare (NASDAQ:SRTS - Free Report) from a hold rating to a sell rating in a report published on Sunday.

Several other brokerages also recently weighed in on SRTS. Maxim Group decreased their target price on shares of Sensus Healthcare from $14.00 to $10.00 and set a "buy" rating for the company in a research note on Monday, May 19th. Lake Street Capital cut their price objective on shares of Sensus Healthcare from $18.00 to $13.00 and set a "buy" rating on the stock in a report on Tuesday, March 11th. Finally, HC Wainwright restated a "buy" rating and set a $12.00 target price on shares of Sensus Healthcare in a research note on Friday, April 4th. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $11.67.

Sensus Healthcare Trading Up 1.9%

Shares of SRTS traded up $0.09 during midday trading on Friday, reaching $4.80. 47,769 shares of the company were exchanged, compared to its average volume of 193,596. Sensus Healthcare has a 1-year low of $4.01 and a 1-year high of $9.33. The stock has a 50-day moving average price of $4.68 and a 200-day moving average price of $5.55. The company has a market cap of $78.91 million, a price-to-earnings ratio of 48.00 and a beta of 1.32.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.20). Sensus Healthcare had a return on equity of 3.34% and a net margin of 4.56%. The company had revenue of $8.34 million for the quarter, compared to analyst estimates of $7.23 million. Equities research analysts anticipate that Sensus Healthcare will post 0.32 earnings per share for the current year.

Hedge Funds Weigh In On Sensus Healthcare

Institutional investors and hedge funds have recently made changes to their positions in the business. Larson Financial Group LLC bought a new stake in shares of Sensus Healthcare in the first quarter worth $26,000. JPMorgan Chase & Co. acquired a new position in Sensus Healthcare during the 4th quarter worth $27,000. Barclays PLC bought a new stake in shares of Sensus Healthcare in the 4th quarter worth about $35,000. BNP Paribas Financial Markets bought a new stake in shares of Sensus Healthcare in the 4th quarter worth about $47,000. Finally, Chapin Davis Inc. raised its stake in shares of Sensus Healthcare by 50.0% in the 1st quarter. Chapin Davis Inc. now owns 15,000 shares of the company's stock valued at $71,000 after purchasing an additional 5,000 shares in the last quarter. 25.30% of the stock is currently owned by hedge funds and other institutional investors.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.